Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) with a $60 price target.
July 17, 2024 | 6:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae has reaffirmed a Buy rating on Arrowhead Pharma with a $60 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $60 price target by Chardan Capital suggests strong confidence in Arrowhead Pharma's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100